{"prompt": "['Product: MK-3475', '145', 'Protocol/Amendment No.: 604-09', 'Abbreviation/Term', 'Definition', 'ECOG', 'Eastern Cooperative Oncology Group', 'eCRF', 'electronic case report form', 'EDC', 'electronic data capture', 'EMA', 'European Medicines Agency', 'EOC', 'Executive Oversight Committee', 'EORTC', 'European Organization for Research and Treatment of Cancer', 'EP', 'etoposide/platinum', 'EQ-5D-5L', 'European Quality of Life Five-dimension Five-level Scale Questionnaire', 'ERC', 'Ethics Review Committee', 'ES-SCLC', 'extensive stage small cell lung cancer', 'FDA', 'Food and Drug Administration', 'FDAAA', 'Food and Drug Administration Amendments Act', 'FSH', 'follicle-stimulating hormone', 'FT4', 'free thyroxine', 'GCP', 'Good Clinical Practice', 'GFR', 'glomerular filtration rate', 'HBsAg', 'hepatitis B surface antigen', 'HCV', 'hepatitis C virus', 'HIV', 'human immunodeficiency virus', 'HR', 'hazard ratio', 'IA1', 'first interim analysis', 'IA2', 'second interim analysis', 'IB', \"Investigator's Brochure\", 'ICH', 'International Council for Harmonization of Technical Requirements for', 'Pharmaceuticals for Human Use (formerly International Conference on', 'Harmonisation)', 'IEC', 'Independent Ethics Committee', 'Ig', 'immunoglobulin', 'IgC', 'immunoglobulin constant', 'IgG', 'immunoglobulin G', 'IgV', 'immunoglobulin variable', 'IHC', 'immunohistochemistry', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '146', 'Protocol/Amendment No.: 604-09', 'Abbreviation/Term', 'Definition', 'INR', 'international normalized ratio', 'irAE', 'immune-related adverse event', 'IRB', 'Institutional Review Board', 'irRECIST', 'Immune-related Response Evaluation Criteria in Solid Tumors', 'IRT', 'interactive response technology', 'ITT', 'intention-to-treat', 'IV', 'intravenous', 'IVRS/IWRS', 'interactive voice response system/integrated web response system', 'LDH', 'lactate dehydrogenase', 'LS-SCLC', 'limited-stage small cell lung cancer', 'MRI', 'magnetic resonance imaging', 'MSD', 'Merk Sharp & Dohme Corp., a subsidiary of Merk & Co., Inc.', 'N/A', 'not applicable', 'NCI', 'National Cancer Institute', 'NSCLC', 'non-small cell lung cancer', 'ORR', 'objective response rate', 'os', 'overall survival', 'OTC', 'over-the-counter', 'PBPK', 'physiologically based pharmacokinetics', 'PCI', 'prophylactic cranial irradiation', 'PD', 'progressive disease', 'PD-1', 'programmed cell death protein-1', 'PD-L1', 'programmed cell death-ligand 1', 'PD-L2', 'programmed cell death-ligand 2', 'PFS', 'progression-free survival', 'PK', 'pharmacokinetic', 'PR', 'partial response', 'PRO', 'patient-reported outcome', 'PT', 'prothrombin time', 'Q2W', 'every 2 weeks', 'Q3W', 'every 3 weeks', 'QLQ-C30', 'Quality of Life Questionnaire Core 30', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '147', 'Protocol/Amendment No.: 604-09', 'Abbreviation/Term', 'Definition', 'QLQ-LC13', 'Quality of Life Questionnaire and Lung Cancer Module 13', 'RBC', 'red blood cell', 'RECIST 1.1', 'Response Evaluation Criteria in Solid Tumors version 1.1', 'RNA', 'ribonucleic acid', 'SAE', 'serious adverse events', 'SAP', 'Statistical Analysis Plan', 'SCLC', 'small cell lung cancer', 'SD', 'stable disease', 'SGOT', 'serum glutamic oxaloacetic transaminase', 'SGPT', 'serum glutamic pyruvic transaminase', 'SOC', 'standard of care', 'sSAP', 'supplemental statistical analysis plan', 'T1DM', 'Type 1 diabetes mellitus', 'T3', 'triiodothyronine', 'TB', 'Bacillum Tuberculosis', 'TIL', 'tumor-infiltrating lymphocyte', 'TSH', 'thyroid-stimulating hormone', 'ULN', 'upper limit of normal', 'WBRT', 'whole brain radiation therapy', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}